[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"embolism-and-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:embolism-and-thrombosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,90,118,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700",false,"NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial","ALL","18 Years",{"count":20,"type":21},276,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[27,28,29,30,31,32,33,34,35],"Pulmonary Embolism","Embolism","Embolism and Thrombosis","Lung Diseases","Cardiovascular Diseases","Respiratory Tract Diseases","Venous Thromboembolism","Anticoagulant-induced Bleeding","Bleeding",[37],"subsegmental pulmonary embolism","RECRUITING","2026-05-20",{"date":41,"type":42},"2026-05-22","ACTUAL",{"date":44,"type":42},"2020-05-15",{"date":46,"type":21},"2028-05",{"name":48,"class":49},"Drahomir Aujesky","OTHER",40,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":71,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100633674","the-recana-for-lower-extremity-venous-obstructions-and-in-stent-restenosis-registry-100633674","NCT07529756","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry","The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry (\"The CALIBER Registry\")","CALIBER","INCLUSION CRITERA:\n\nA. Native Vessel:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Proximal lower extremity obstruction\u002Focclusion involving the femoral, common femoral, iliac veins, or inferior vena cava (IVC), alone or in combination that in the opinion of the investigator, treatment with the Recana would benefit the patient\n3. INC-3: Recana Thrombectomy Catheter System must enter vasculature\n4. INC-4: Willing and able to provide written informed consent\n\nB. In-Stent Restenosis:\n\n1. INC-1: Subject is 18 years or older\n2. INC-2: Subjects with stents implanted greater than 6 weeks prior to index procedure\n3. INC-3: Location of thrombosed stents in proximal lower extremity deep vein segments including common femoral, external iliac, common iliac vein, or inferior vena cava alone or in combination that in the opinion of the investigator treatment with the Recana would benefit the patient\n4. INC-4: Recana Thrombectomy Catheter System must enter vasculature\n5. INC-5: Willing and able to provide written informed consent\n\nEXCLUSION CRITERA\n\nA. Native Vessel:\n\n1. EXC-1: IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n2. EXC-2: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n3. EXC-3: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n4. EXC-4: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n5. EXC-5: Severe, life-threatening allergy to iodine or contrast dye\n6. EXC-6: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n7. EXC-7: Life expectancy less than 1 year\n8. EXC-8: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n9. EXC-9: Known hypercoagulable states that, in the opinion of the investigator, cannot be medically managed throughout the study period\n10. EXC-10: Inability to secure venous access and cross lesion\n11. EXC-11: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n12. EXC-12: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed\n\nB. In-Stent Restenosis:\n\n1. EXC-1: Exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel\n2. EXC-2: Stent failure caused by undersizing or malapposition of the stent(s) \\[For example, the segment of a stent in the iliac vein that is not wall apposed or cannot be apposed to the wall after balloon dilation is excluded. The segment of a stent that extends into the IVC that is not wall apposed would not be excluded.\\]\n3. EXC-3: Stents compressed to \\\u003C6mm that remain \\\u003C6mm after balloon dilation\n4. EXC-4: IVC filter in place at the time of index procedure that, in the judgment of the investigator, may interfere with the procedure\n5. EXC-5: Congenital anatomic anomalies of the iliac veins that in the opinion of the investigator would preclude treatment with the Recana\n6. EXC-6: Heparin allergy or hypersensitivity that cannot be adequately managed with alternate anticoagulant during or after the procedure, or prior diagnosis of HIT (Heparin-Induced Thrombocytopenia)\n7. EXC-7: Severe, life-threatening allergy to iodine or contrast dye\n8. EXC-8: Any contraindication to anticoagulants or antiplatelets that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n9. EXC-9: Life expectancy less than 1 year\n10. EXC-10: Chronic non-ambulatory status such as long-term wheelchair requirement or bedridden status\n11. EXC-11: Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n12. EXC-12: Inability to secure venous access and cross lesion\n13. EXC-13: Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject\n14. EXC-14: Current active participation in another investigational drug or device study in which the primary endpoint has not been analyzed",{"count":60,"type":21},87,"1 Year","OBSERVATIONAL","The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions. The main questions the study aims to answer are:\n\n* What is the observed rate of safety events through the 30-day follow-up?\n* What is the rate of technical success (acute procedural success) achieved at the index procedure?\n\nParticipants already undergoing treatment with the Recana as part of their regular medical care will be followed for 1 year.",[65,66,67,68,69,29,70],"Chronic Venous Disease","Chronic Venous Insufficiency, CVI","Venous Thrombosis","Thrombosis (Stent Thrombosis)","Thrombosis, Venous","Thrombectomy",[72,73,74,75,76,77,78],"in-stent restenosis","venous obstruction or occlusion","thrombus","emboli","CALIBER Registry","recanalization","debulking","NOT_YET_RECRUITING","2026-05-07",{"date":82,"type":42},"2026-05-12",{"date":84,"type":21},"2026-06",{"date":86,"type":21},"2029-03",{"name":88,"class":89},"Intervene, Inc.","INDUSTRY",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100482971","collection-of-blood-samples-for-new-diagnostic-devices-2-100482971","NCT05568966","Collection of Blood Samples for New Diagnostic Devices 2","Collection of Venous and Capillary Blood Samples for the Research, Optimisation and Calibration of New Diagnostic Devices 2","NOVEL-2","Inclusion Criteria\n\n* Subject 18 years of age.\n* Willing and able to provide written informed consent and comply with study procedures.\n* Patients attending a definitive care team with research capabilities which has been enroled in this collection study.\n* Patients who can read and understand written English.\n* The subject must present as one of the following cohorts:\n\n  1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.\n  2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.\n  3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.\n  4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.\n  5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.\n\nExclusion Criteria\n\n* Subject \\\u003C18 years of age.\n* Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.\n* Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.",{"count":99,"type":21},20000,[101],"NA","To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.",[29,104,105,106,107],"Cardiovascular","Renal","Inflammation","Infections","2026-04-17",{"date":110,"type":42},"2026-04-22",{"date":112,"type":42},"2022-07-11",{"date":114,"type":21},"2026-08-20",{"name":116,"class":89},"LumiraDx UK Limited",7,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100532214","prolonged-anticoagulation-therapy-on-the-prognosis-of-patients-with-left-ventricular-thrombosis-100532214","NCT06209892","Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis","Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular","Inclusion Criteria:\n\n①Patients who have been clearly diagnosed with left ventricular thrombus by inpatient or outpatient cardiac ultrasound (including general ultrasound and acoustic imaging).\n\n②Age \\>= 18 years old\n\nExclusion Criteria:\n\n* Patients do not agree to participate in the study or have poor compliance in the past\n\n  * Contraindication to anticoagulation or allergy to anticoagulants ③Have received oral anticoagulation after diagnosis of left ventricular thrombus.\n\n    * Have undergone or are planning to undergo surgical procedures including left ventricular appendage thrombectomy, heart transplantation, ventricular wall tumor collapse, or valve replacement.\n\n      * Presence of other long-term indications for anticoagulation, such as mechanical valve implantation, atrial fibrillation, etc.\n\n        * Requirement for treatment with Tegretol and inability to change to clopidogrel bisulfate ⑦Presence of known malignant tumors, severe hepatic dysfunction (Child-Pugh classification B or less), severe renal dysfunction (creatinine clearance \\\u003C30ml\u002Fmin), anemia (Hb \\\u003C100g\u002FL), coagulation disorders and other underlying diseases, or life expectancy \\\u003C3 years ⑧ Female patients are pregnant or breastfeeding ⑨ Patients with antiphospholipid syndrome",{"count":126,"type":21},220,[101],"A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation, helps to reduce major adverse cardiovascular and cerebrovascular events in patients with left ventricular thrombosis and to reduce recurrence of thrombosis, as well as to assess their bleeding risk.\n\nPatients with a definite diagnosis of left ventricular thrombus and age ≥18 years were included in cardiac ultrasound (including general ultrasound and sonography) and other examinations during hospitalization and outpatient visits. Exclusion criteria were detailed in the study protocol.\n\nGROUPING: According to the duration of anticoagulation, they were divided into extended anticoagulation group (12 months) and conventional anticoagulation group (6 months).\n\nINTERVENTION: This study is planned to extend the administration of rivaroxaban (Pulsatilla) 20 mg to 12 months in the experimental group. The conventional anticoagulation group will take the drug for 6 months Study Endpoints: The primary efficacy endpoint is a major cardiovascular-vascular adverse event at 1 year; the primary safety endpoint is bleeding of grade 3 or higher as defined by the BARC classification at 1 year.\n\nPatient Follow-up Program: Subjects will require a total of 12 on-site follow-up visits (one per month) for safety evaluation, efficacy evaluation, medication adherence evaluation, and imaging follow-up at months 3, 6, and 12.",[29,130],"Anticoagulation","2024-01-06",{"date":133,"type":42},"2024-01-18",{"date":135,"type":21},"2024-01",{"date":137,"type":21},"2027-12",{"name":139,"class":49},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100504858","observational-dutch-young-symptomatic-stroke-study---next-100504858","NCT05853796","Observational Dutch Young Symptomatic StrokE studY - nEXT","Observational Dutch Young Symptomatic StrokE studY - Extended","ODYSSEY-nEXT","Inclusion Criteria:\n\n* Patients with a first-ever transient ischemic attack (TIA) or acute ischemic stroke aged between 18 and 50 years old\n* For this study, acute stroke is defined as \"occurence of acute neurological deficit lasting more than 24 hours, with confirmation on imaging (CT(-a) or MR(-a))\".TIA is defined as \"occurence of acute neurological deficit lasting less than 24 hours with confirmation of ischemia on MRI).\n* Patients have a kidney function eGFR\\>30ml\u002Fmin.\n\nExclusion Criteria:\n\n* A history of clinical TIA, ischemic stroke or intracerebral hemorrhage\n* A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy.\n* A venous infarction, retinal infarction or amourosis fugax.\n* Inadequate control of the Dutch language to reliably sign an informed consent from and\u002For participate in the follow-up\n* Patients are excluded if they have a contra indication for 3T MRI.","50 Years",{"count":150,"type":21},280,"BACKGROUND: Worldwide, 2 million patients aged 18-50 years suffer an ischemic stroke each year with an increasing trend over the past decade due to yet unknown reasons. Whereas prognosis and antithrombotic treatment in older patients with cardiovascular disease are among the best studied topics in clinical medicine, this does not hold true for patients at young age. It is of great importance to treat these patient groups correctly to prevent recurrence and bleeding complications. However, previous research have shown that there is a long-term increased risk of recurrent ischemic events despite the secondary prevention and a subsequent increased bleeding risk. To tailor effective antithrombotic therapy to the individual patient, it is essential to understand the underlying pathogenesis and identify modifiable risk factors in young patients for recurrence or bleeding. It is thought that abnormalities of hemostasis may play a key role in early-onset ischemic stroke. First, prothrombotic conditions are associated with an increased risk for ischemic stroke at young age. In addition, disturbance of the hemostatic balance due to one or several triggers can activate the coagulation cascade, which on its turn can lead or contribute to clot formation and subsequent arterial occlusion. In previous study, there were indications that trigger factors such as fever and\u002For an infection in the days prior to the stroke may play a role in the pathogenesis. This suggests that an interaction between inflammation, endothelial damage and coagulation may lead to the formation of a clot. In this observational study we aim to investigate the role of the immune system, endothelial damage and coagulation in the pathogenesis and prognosis of stroke in young patients.\n\nOBJECTIVE: To investigate the role of hemostasis, inflammation and endothelial activation in the etiology and prognosis in an acute ischemic stroke (or TIA) in young stroke patients.\n\nSTUDY DESIGN: Multicentre prospective observational study\n\nSTUDY POPULATION:\n\nAll patients aged between 18 and 50 years old with a first-ever ischemic stroke or TIA who are admitted to the neurology ward or seen at the outpatient clinic of one of the participating centers.\n\nMain exclusion criteria are: history of clinical TIA, ischemic stroke or intracerebral hemorrhage. A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy. A venous infarction, retinal infarction and amourosis fugax. Inadequate control of the Dutch language to reliably sign an informed consent from and\u002For participate in the follow-up. Patients are excluded if they have a contra indication for 3T MRI.\n\nIn addition 60 healthy controls (18-50 years old) will be included.\n\nMAIN STUDY ENDPOINTS:\n\n1. Baseline and 3 months coagulation profile:\n\n   Whole blood and platelet poor plasma thrombin generation, platelet function tests, and coagulation biomarkers, screening for thrombophilia.\n2. Baseline and 3 months inflammation\u002Fendothelial activation profile:\n\n   Cytokines\u002Fchemokines, expression of receptors\u002Fcofactors related to hemostasis on peripheral blood mononuclear cells (PBMCs), stimulation tests of PBMC's to assess trained immunity.\n3. Vessel wall enhancement on 3 Tesla MRI\n4. Questionnaire trigger factors",[153,154,31,155,29,156,157],"Ischemic Stroke","Stroke in the Young","Cerebrovascular Disorders","Thrombophilia","Coagulation","2023-05-02",{"date":160,"type":42},"2023-05-11",{"date":162,"type":42},"2023-02-06",{"date":164,"type":21},"2037-01-01",{"name":166,"class":49},"Radboud University Medical Center",6]